



1/89




FIG. 1

BEST AVAILABLE COPY

2/89




FIG. 2

3/89




FIG. 3

4/89




FIG. 4




FIG. 5

5/89






FIG. 6B


FIG. 6A

6/89



**7/89**

**8/89**








FIG. 9

10/89






FIG. 10

**11/89**



**FIG. 11A**



**FIG. 11B**

12/89




FIG. 12




FIG. 13

13/89





FIG. 14A

14/89



**FIG. 14B**

15/89




FIG. 15A

16/89

*99m* Tc-EC-Nitroimidazole (NIM)  
(100 $\mu$ Ci/mouse, iv.)





FIG. 15B



17/89

*<sup>99m</sup>Tc-EC-Nitroimidazole (NIM)*



18/89




FIG. 15D

19/89




FIG. 16

20/89




FIG. 17

21/89




FIG. 18

22/89





FIG. 19A


23/89

***$^{99m}\text{Tc}$ -EC-Annexin V  
(100  $\mu\text{Ci}$ /mouse, iv.)***



**FIG. 19B**

24/89





25/89





FIG. 20B

**26/89****FIG. 21**

27/89




FIG. 22

28/89




FIG. 23





FIG. 24


**29/89**



**FIG. 25**



**FIG. 26**

**30/89****FIG. 27**

31/89




FIG. 28



FIG. 29

32/89




FIG. 30




FIG. 31



**33/89**




**FIG. 33**



**FIG. 32**

**34/89**



**FIG. 34**



**FIG. 35**

35/89




FIG. 36

36/89






FIG. 37A

**37/89**



**FIG. 37B**


**38/89**



**<sup>1</sup>H-NMR of EC.**

**FIG. 38A**


**39/89**



**$^1\text{H}$ -NMR of neomycin**

**FIG. 38B**

40/89



<sup>1</sup>H-NMR of EC-neomycin

FIG. 38C



41/89




FIG. 39

42/89




FIG. 40A







FIG. 40B

**43/89****FIG. 40C****FIG. 41**

**44/89**

$^{99m}\text{Tc}$ -EC-NEO



**FIG. 42**

45/89

$^{99m}\text{Tc}$ -EC-NEO




FIG. 43

$^{18}\text{F}$ -FDG





FIG. 44

**46/89**

*<sup>18</sup>F-FDG*



**FIG. 45**

47/89






FIG. 46

48/89






49/89



50/89



AGENT (dose)  
FIG. 48B

51/89




FIG. 49








FIG. 59

**52/89****FIG. 50****FIG. 51**

**53/89**




**FIG. 52**




**FIG. 53**

**54/89**




**FIG. 54**

55/89





56/89






57/89



**58/89****FIG. 56**

59/89




Inventor: David J. Yang et al.

Serial No. 09/599,152

Title: Ethylenedicysteine (EC)-Drug Conjugates, Compositions  
and Methods for Tissue Specific Disease Imaging

Filed: June 21, 2000

60/89

TIME  
FIG. 58

61/89






FIG. 60

**62/89**




**FIG. 61**




**FIG. 62**

**63/89**




**FIG. 63**




**FIG. 64A**

**64/89**



**FIG. 64B**



**FIG. 65**




Inventor: David J. Yang et al.

Serial No. 09/599,152


Title: Ethylenedicysteine (EC)-Drug Conjugates, Compositions  
and Methods for Tissue Specific Disease Imaging

Filed: June 21, 2000

**65/89**



**FIG. 66**



**FIG. 67**

66/89




FIG. 68

67/89




FIG. 69

68/89





FIG. 70

69/89



70/89




FIG. 72

Inventor: David J. Yang et al.

Serial No. 09/599,152

Title: Ethylenedicysteine (EC)-Drug Conjugates, Compositions  
and Methods for Tissue Specific Disease Imaging

Filed: June 21, 2000

71/89






FIG. 73

72/89





73/89



74/89





FIG. 76

75/89






FIG. 78

77/89




FIG. 79

78/89




FIG. 80

79/89






FIG. 81

**80/89**



*POST OP*

**FIG. 82A**



*PRE OP*



81/89





FIG. 82B

82/89



POST-OP

FIG. 83A

PRE-OP

83/89





FIG. 83B

**84/89**



**FIG. 84A**



**FIG. 85A**

85/89




FIG. 84B

86/89




FIG. 85B

87/89





FIG. 86A

88/89





89/89




FIG. 86C

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**